Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
Who is this study for? Patients with retinitis pigmentosa
What treatments are being studied? BS01
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed diagnosis of retinitis pigmentosa
• At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Locations
United States
New Jersey
New Jersey Retina
RECRUITING
Teaneck
Contact Information
Primary
Minako Koga
mkoga@kmphc.com
Time Frame
Start Date: 2020-02-06
Estimated Completion Date: 2029-12-30
Participants
Target number of participants: 20
Treatments
Experimental: Cohort 1
BSO1 Cohort 1 dose
Experimental: Cohort 2
BS01 Cohort 2 dose
Experimental: Cohort 3
BS01 Cohort 3 dose
Experimental: Cohort 4
BS01 Cohort4 dose
Experimental: Cohort 5
BS01 Cohort4 dose
Experimental: Cohort 6
Treat opposite eye
Authors
Related Therapeutic Areas
Sponsors
Leads: Bionic Sight LLC